A Phase I/II trial of Cetuximab, Carboplatin and Radiotherapy for patients with locally advanced Head and Neck Squamous Cell Carcinoma.

The purpose of this study is to assess the safety and feasibility of combining radiotherapy and carboplatin (a chemotherapy drug) with a new drug called cetuximab in patients with locally advanced head and neck cancer

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Final Accrual

60

Trial Chairperson

Assoc Prof June Corry, Peter MacCallum Cancer Centre, VIC
Prof Danny Rischin, Peter MacCallum Cancer Centre, VIC

Clinical Trial Registration

Related Post

22 June, 2026

Novel lung cancer radiation therapy approach to be tested in new PRIME-Lung trial

LATEST NEWS: 22 June 2026 In an important step

Facility Alliance Member in Focus
17 June, 2026

TROG Facility Alliance Member in Focus: Radiation Oncology Network, Western Sydney Local Health District

TROG’s Facility Alliance Members (FAM) are the cornerstone of